Wedbush Securities Inc. raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.1% during the second quarter, Holdings Channel reports. The fund owned 8,233 shares of the medical research company’s stock after buying an additional 400 shares during the period. Wedbush Securities Inc.’s holdings in Edwards Lifesciences Corporation were worth $973,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Macquarie Group Ltd. raised its stake in Edwards Lifesciences Corporation by 56.9% in the fourth quarter. Macquarie Group Ltd. now owns 149,380 shares of the medical research company’s stock valued at $13,996,000 after buying an additional 54,196 shares during the last quarter. Gulf International Bank UK Ltd raised its stake in Edwards Lifesciences Corporation by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 65,780 shares of the medical research company’s stock valued at $6,187,000 after buying an additional 900 shares during the last quarter. Quadrant Capital Group LLC raised its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the last quarter. National Pension Service raised its stake in Edwards Lifesciences Corporation by 6.2% in the first quarter. National Pension Service now owns 180,399 shares of the medical research company’s stock valued at $16,932,000 after buying an additional 10,502 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Edwards Lifesciences Corporation by 31.6% in the first quarter. Bank of Montreal Can now owns 189,685 shares of the medical research company’s stock valued at $17,842,000 after buying an additional 45,525 shares during the period. Hedge funds and other institutional investors own 84.15% of the company’s stock.

Shares of Edwards Lifesciences Corporation (EW) opened at 114.50 on Friday. The firm has a market capitalization of $24.18 billion, a P/E ratio of 34.73 and a beta of 0.63. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The firm has a 50-day moving average of $116.95 and a 200-day moving average of $105.35.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.76 earnings per share. On average, equities analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/13/wedbush-securities-inc-acquires-400-shares-of-edwards-lifesciences-corporation-nyseew.html.

Several brokerages have recently issued reports on EW. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, May 18th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Bank of America Corporation boosted their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. SunTrust Banks, Inc. boosted their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a report on Monday, July 17th. Finally, Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, April 26th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Patrick B. Verguet sold 11,500 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $111.64, for a total transaction of $1,283,860.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total value of $3,816,071.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 183,412 shares of company stock worth $21,176,230. 2.13% of the stock is owned by company insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.